Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
To detail recent developments pertaining to the efficacy and safety of radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan for patients with B-cell non-Hodgkin's lymphoma (NHL). Published clinical trials of 90Y ibritumomab tiuxetan and secondary literature on radioimmunotherapy and NHL. Yttrium 90 ibritumomab tiuxetan is safe and effective in the indicated population. It has a good safety profile and is generally well tolerated. It is not associated with the adverse events from conventional chemotherapy and external beam radiation therapy. Nursing professionals who are aware of the efficacy and safety data associated with 90Y ibritumomab tiuxetan can optimize efficacy and educate patients and their caregivers about the regimen.